Catalent (NYSE:CTLT) Rating Lowered to “Sell” at StockNews.com

Catalent (NYSE:CTLT) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

A number of other equities research analysts also recently weighed in on the stock. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Royal Bank of Canada restated a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, July 11th. Robert W. Baird restated a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. Finally, William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $59.83.

Catalent Price Performance

Catalent stock traded up $1.47 during trading hours on Wednesday, reaching $59.95. 4,195,865 shares of the stock were exchanged, compared to its average volume of 2,049,190. The stock has a 50 day moving average of $60.03 and a two-hundred day moving average of $58.03. Catalent has a twelve month low of $32.38 and a twelve month high of $61.20. The company has a current ratio of 2.52, a quick ratio of 1.96 and a debt-to-equity ratio of 1.35. The company has a market cap of $10.88 billion, a P/E ratio of -10.92, a price-to-earnings-growth ratio of 2.06 and a beta of 1.16.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the previous year, the business posted ($0.10) earnings per share. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. Equities analysts expect that Catalent will post 0.95 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Catalent

A number of hedge funds have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Catalent by 33.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,789 shares of the company’s stock worth $1,230,000 after buying an additional 5,499 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Catalent by 154.6% during the first quarter. BNP Paribas Financial Markets now owns 216,311 shares of the company’s stock valued at $12,211,000 after purchasing an additional 131,360 shares during the last quarter. Nordea Investment Management AB lifted its holdings in Catalent by 10.2% during the first quarter. Nordea Investment Management AB now owns 11,874 shares of the company’s stock valued at $672,000 after purchasing an additional 1,096 shares during the last quarter. Daiwa Securities Group Inc. lifted its holdings in Catalent by 8.3% during the first quarter. Daiwa Securities Group Inc. now owns 26,397 shares of the company’s stock valued at $1,490,000 after purchasing an additional 2,017 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Catalent during the first quarter valued at about $625,000.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.